AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteMK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively.
More Information Supplier PageMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
More Information Supplier PageMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
More Information Supplier PageMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
More Information Supplier PageMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
More Information Supplier PageMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
More Information Supplier PageMK-2894 is a highly potent and selective second generation EP4 antagonist.
More Information Supplier PageMK-2894 is a highly potent and selective second generation EP4 antagonist.
More Information Supplier PageMK-2894 is a highly potent and selective second generation EP4 antagonist.
More Information Supplier PageMK-2894 is a highly potent and selective second generation EP4 antagonist.
More Information Supplier PageMK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.
More Information Supplier PageMK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.
More Information Supplier PageMK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.
More Information Supplier PageMK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists.
More Information Supplier PageMK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists.
More Information Supplier PageMK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists.
More Information Supplier PageSuvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.
More Information Supplier PageSuvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.
More Information Supplier PageSuvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.
More Information Supplier PageSuvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.
More Information Supplier PageSuvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.
More Information Supplier PageMK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
More Information Supplier PageMK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
More Information Supplier PageMK-5108, also known as VX-689, is a competitive inhibitor of the ATP-binding site of aurora A kinase.
More Information Supplier PageMK-5108, also known as VX-689, is a competitive inhibitor of the ATP-binding site of aurora A kinase.
More Information Supplier PageMK-5108, also known as VX-689, is a competitive inhibitor of the ATP-binding site of aurora A kinase.
More Information Supplier PageMK-5108, also known as VX-689, is a competitive inhibitor of the ATP-binding site of aurora A kinase.
More Information Supplier PageMK-5108, also known as VX-689, is a competitive inhibitor of the ATP-binding site of aurora A kinase.
More Information Supplier PageMK-5172 is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
More Information Supplier PageMK-5172 is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
More Information Supplier PageMK-5172 is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
More Information Supplier PageMK-8245 is a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor. MK-8245 is useful for the Treatment of Diabetes and Dyslipidemia.
More Information Supplier PageMK-8245 is a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor. MK-8245 is useful for the Treatment of Diabetes and Dyslipidemia.
More Information Supplier PageMK-8245 is a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor. MK-8245 is useful for the Treatment of Diabetes and Dyslipidemia.
More Information Supplier PageMK-8245 is a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor. MK-8245 is useful for the Treatment of Diabetes and Dyslipidemia.
More Information Supplier PageMK-8245 is a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor. MK-8245 is useful for the Treatment of Diabetes and Dyslipidemia.
More Information Supplier PageMK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.
More Information Supplier Page
